Title:
N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2018/214867
Kind Code:
A1
Abstract:
An N-(azaaryl)cyclolactam-1-carboxamide derivative having a structure of formula (1), a preparation method therefor, and a use thereof, each substituent being defined in the description and claims. The compound can be widely applied to the preparation of medicaments for treating cancer, tumor, autoimmune diseases, metabolic diseases, or metastatic diseases, in particular for treating ovarian cancer, pancreatic cancer, prostate cancer, breast cancer, cervical cancer, glioblastoma, multiple myeloma, metabolic diseases, neurodegenerative diseases, metastasis of primary tumor sites, or bone metastatic cancer, and is expected to be developed into CSF1R inhibitor drugs.
Inventors:
ZHAO BAOWEI (CN)
ZHANG MINGMING (CN)
YU HONGPING (CN)
YANG SHUQUN (CN)
CHEN ZHUI (CN)
XU YAOCHANG (CN)
ZHANG MINGMING (CN)
YU HONGPING (CN)
YANG SHUQUN (CN)
CHEN ZHUI (CN)
XU YAOCHANG (CN)
Application Number:
PCT/CN2018/087807
Publication Date:
November 29, 2018
Filing Date:
May 22, 2018
Export Citation:
Assignee:
ABBISKO THERAPEUTICS CO LTD (CN)
International Classes:
C07D401/14; A61K31/4439; A61K31/497; A61P3/00; A61P35/00; A61P37/00; C07D413/14; C07D417/14
Domestic Patent References:
WO2014145015A2 | 2014-09-18 | |||
WO2014145028A2 | 2014-09-18 | |||
WO2014145023A1 | 2014-09-18 | |||
WO2006067445A2 | 2006-06-29 | |||
WO2014145028A2 | 2014-09-18 |
Other References:
EXPERT OPIN THER PAT., vol. 21, no. 2, February 2011 (2011-02-01), pages 147 - 65
CURR OPIN PHARMACOL., vol. 23, August 2015 (2015-08-01), pages 45 - 51
FRONT PHARMACOL., vol. 8, 8 February 2017 (2017-02-08), pages 49
NAT REV DRUG DISCOV., vol. 14, no. 9, September 2015 (2015-09-01), pages 603 - 22
NATURE REVIEWS CLINICAL ONCOLOGY, vol. 14, 2017, pages 131 - 132
NAT MED., vol. 19, no. 10, October 2013 (2013-10-01), pages 1264 - 72
PLOS ONE, vol. 7, no. 12, pages e50946
CANCER CELL., vol. 25, no. 6, 16 June 2014 (2014-06-16), pages 846 - 59
R B SILVERMANM HALLADAY: "The Organic Chemistry of Drug Design and Drug Action", 1 January 2014, ELSEVIER, ISBN: 978-0-12-382030-3, article SILVERMAN RICHARD B., HOLLADAY MARK W.: "Lead Discovery and Lead Modification", pages: 19 - 122, XP055964547, DOI: 10.1016/B978-0-12-382030-3.00002-7
See also references of EP 3632907A4
CURR OPIN PHARMACOL., vol. 23, August 2015 (2015-08-01), pages 45 - 51
FRONT PHARMACOL., vol. 8, 8 February 2017 (2017-02-08), pages 49
NAT REV DRUG DISCOV., vol. 14, no. 9, September 2015 (2015-09-01), pages 603 - 22
NATURE REVIEWS CLINICAL ONCOLOGY, vol. 14, 2017, pages 131 - 132
NAT MED., vol. 19, no. 10, October 2013 (2013-10-01), pages 1264 - 72
PLOS ONE, vol. 7, no. 12, pages e50946
CANCER CELL., vol. 25, no. 6, 16 June 2014 (2014-06-16), pages 846 - 59
R B SILVERMANM HALLADAY: "The Organic Chemistry of Drug Design and Drug Action", 1 January 2014, ELSEVIER, ISBN: 978-0-12-382030-3, article SILVERMAN RICHARD B., HOLLADAY MARK W.: "Lead Discovery and Lead Modification", pages: 19 - 122, XP055964547, DOI: 10.1016/B978-0-12-382030-3.00002-7
See also references of EP 3632907A4
Attorney, Agent or Firm:
XU & PARTNERS, LLC. (CN)
Download PDF: